Company intelligence / Profile preview

Wellbeing Digital Sciences

London, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Wellbeing Digital Sciences delivers ketamine-assisted therapy through North American clinics and is pursuing research and partnering for clinical studies of new psychedelic drugs, mainly targeting mental health disorders and rare neurodevelopmental indications. Its KGK Science subsidiary provides CRO services for clinical trials in pharmaceuticals, cannabis, natural health products, and psychedelics, including pioneering regulatory and efficacy work in psilocybin for autism and Fragile X Syndrome[1][2][3][4][5][6][9].

Therapeutic areas: NeurologyPsychiatry
Modalities: DeviceSmall moleculeBiologic
Industry: Biotech

Partnerships

Nova Mentis Life Science Corp.Unifor (Canada's largest private-sector union)Cognetivity Neurosciences

Beyond the preview

Go deeper on Wellbeing Digital Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellbeing Digital Sciences.

Explore the full profile